The Cancer Vaccine That Could Save Moderna

Moderna's stock dropped over 90% from its peak and the company was bleeding cash.

The vaccine results could be one of the biggest advancements in cancer in the last 25 years.

mRNA acts as a temporary instruction manual that shuttles directions from DNA to different parts of the body.

Picking the wrong biology could make people blame the mRNA technology instead of the disease target.

Stephen Hoge was the dreamer and scientist who believed in turning medicine into information.

A hedge fund manager sent a $500,000 check that launched Moderna's oncology program.

Merck agreed to pay $200 million to fund the research despite initial doubts about whether it would work.

Moderna had to choose between treating cancer patients or making doses for the global public.

Moderna generated $36 billion in COVID vaccine sales but later cut jobs and research programs.

The phase three trial included over 1,000 high-risk melanoma patients.

CEO Stephane Bancel declared, 'We are now an oncology company,' signaling a major strategic shift.

The Trump administration has shown skepticism about mRNA technology.

The new treatment will be priced less than other cancer therapies that can cost up to $500,000.